IDEX Corporation (IEX) — Q2 2026 Earnings Preview

1. Earnings Preview

Key Takeaway: The setup favors a beat — consensus sits below Q1's run-rate on both revenue and EPS, HST's record backlog provides strong visibility, and management guided Q2 organic growth of 3–4% with adjusted EPS of $2.07–$2.12, a bar the Street appears to have set conservatively. The single biggest swing factor is whether HST's AI/data-center and semiconductor momentum continues to outpace the flattish FMT and FSDP backdrop.

IDEX heads into Q2 2026 earnings with a constructive setup built on the back of a strong Q1 beat and guidance raise. Consensus revenue of ~$905M implies modest sequential growth from Q1's $887M, while the adjusted EPS consensus of ~$1.77 sits comfortably within management's guided range of $2.07–$2.12 — a gap that reflects the Street's tendency to anchor below the midpoint of guidance after a quarter where IEX beat by a wide margin. The guidance tone from the April 29 call was notably confident: management raised full-year organic growth guidance from 1–2% to 3–4% and lifted adjusted EPS guidance by $0.20 to $8.35–$8.55, driven almost entirely by HST momentum rather than any cyclical industrial recovery. Estimate revisions have been modestly positive since the Q1 print, with FY2026 EPS consensus edging up from ~$7.14 to ~$7.16, suggesting the Street has largely digested the raise without chasing it higher — leaving room for another positive surprise if HST order conversion continues at its Q1 pace. The stock has rallied ~3.4% since the Q1 earnings date (April 29) versus XLI's +7.4%, meaning IEX has actually lagged the industrial sector despite the strong print, which argues the multiple is not stretched and a beat would be rewarded. The key wildcard is life sciences: management guided this sub-segment to return to flat-to-slight growth in the balance of 2026, but NIH/academic funding headwinds and China market pressure remain live risks that could weigh on HST mix and margins even if the headline order number holds.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus sets a manageable bar — Q2 revenue of ~$905M and adjusted EPS of ~$1.77 both sit below Q1 actuals on a sequential basis, and the EPS consensus is well below the midpoint of management's own $2.07–$2.12 guidance. Total orders and HST organic growth are the bigger swing factors: a repeat of Q1's record $988M orders and 17% HST organic order growth would signal durable backlog build and likely drive upside to both revenue and margin.

Table 1 — Q2 2026 Current Quarter Snapshot

Sources: Visible Alpha Consensus and Actuals Data — Net sales, EPS-Diluted Operating, Total Orders, Orders Organic Impact, Organic Impact, EBITDA Margin Operating, HST/FMT/FSDP Net Sales. Q2 2026 guidance from IDEX Q1 2026 Earnings Release and Earnings Call (April 29, 2026).

Table 2 — Beat/Miss History: Last 8 Quarters (Top 2 KPIs: Net Sales & Adj. EPS - Operating)

Pattern: IEX has beaten revenue consensus in 6 of the last 7 reported quarters and beaten adjusted EPS in 5 of 7, with the lone double-miss in Q4 2024 followed by a recovery trend. The Q1 2026 EPS beat of +15.4% was the largest in the trailing eight quarters, driven by HST outperformance. Source: Visible Alpha Consensus and Actuals Data.

3. Guidance & Commentary Evolution

Key Takeaway: Management raised both organic growth and EPS guidance meaningfully at Q1 earnings (April 29) and has not issued any subsequent revisions — the Q2 guide of $2.07–$2.12 adj. EPS and 3–4% organic growth stands as the current baseline. Tone is notably confident on HST and cautiously constructive on FMT/FSDP, with no post-earnings guidance changes or 8-K updates since the May 8 shareholder vote.

Sources: IDEX Q1 2026 Earnings Release and Earnings Call Transcript (April 29, 2026); Visible Alpha Consensus and Actuals Data.

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates for Q2 2026 and FY2026 have been largely stable since the Q1 print, with revenue consensus essentially flat and EPS consensus edging marginally higher. The persistent gap between the Street's EPS consensus and management's guidance midpoint is the most notable feature — it represents either a significant cushion for a beat or a sign that the Street is skeptical of the guidance range. Given IEX's track record of beating, the former interpretation appears more likely.

The striking feature of this table is the persistent ~16% gap between the Street's EPS consensus and management's guidance midpoint for both Q2 and FY2026. Revenue and margin estimates are well-anchored near the guidance midpoint, suggesting the Street trusts the top-line and margin framework but is applying a discount to the EPS conversion — possibly reflecting uncertainty around below-segment-average margins in recently acquired HST businesses (Mott, Muon Micro, Muon Lamb) and the pace of 8020 margin improvement. If HST continues to convert its record backlog at Q1's pace, the EPS gap is the most likely source of upside surprise. Source: Visible Alpha Consensus and Actuals Data; IDEX Q1 2026 Earnings Call (April 29, 2026).

5. Stock Performance

Key Takeaway: IEX has lagged XLI by ~400 bps since the Q1 earnings date despite a strong beat-and-raise, suggesting the stock's re-rating has been driven by multiple expansion in the broader industrial sector rather than IEX-specific earnings revisions. The relative underperformance vs. XLI creates a lower-risk entry point ahead of Q2 — a beat would likely close the gap, while a miss would be punished from a less-stretched starting multiple.

Since the Q1 2026 earnings date (April 29, 2026), IEX has returned approximately +3.4% (from $217.34 to $224.65 as of July 29, 2026), compared to XLI's +7.4% (from $169.93 to $182.49) and SPY's +4.1% (from $711.58 to $740.86). IEX's NTM EV/EBITDA multiple currently stands at 17.7x, up from ~16.9x three months ago (+4.9% multiple expansion), with the 12-month price gain of +21.0% decomposing into ~13.9% multiple expansion and ~7.1% earnings growth contribution. The stock's relative underperformance vs. XLI since Q1 earnings is notable given the magnitude of the beat, and likely reflects the market's skepticism about the sustainability of HST's AI/data-center-driven growth and the absence of a cyclical industrial recovery in FMT/FSDP. Source: Stock Price Data (Yahoo Finance); Stock Performance Decomposition Data.

Indexed Performance Since Q1 2026 Earnings (April 29, 2026 = 100):

Note: IEX initially sold off ~4% in the two weeks following the Q1 earnings beat (May 1–15), likely reflecting profit-taking after the strong intraday surge on April 29. The stock recovered through June, briefly outperforming XLI in mid-June before lagging again in July. The July 16 intraday high of $228.96 was the peak since the Q1 print. Source: Stock Price Data (Yahoo Finance).

6. Material News & Developments

Key Takeaway: The most important development since Q1 earnings is the confirmation of Q2 earnings on July 29 with no pre-announcement or guidance revision — silence is constructive. Peer prints from DOV and XYL (both reporting Q2 2026 this week) provide broadly positive read-throughs for IEX's end markets.

• July 29, 2026 — Q2 2026 Earnings Release (Today): IDEX scheduled to report Q2 2026 results pre-market with an 8:00 a.m. CT investor call. No pre-announcement or guidance revision was issued, which is constructive — management's silence since April 29 suggests results are tracking within or above the guided range.
• July 28, 2026 — Xylem (XYL) Q2 2026 Results: XYL reported mixed results — inline sales, EPS upside, and orders surging +41% organically. Organic sales guidance trimmed slightly (2–3% vs. prior 2–4%) due to electric metering project delays, but EPS guidance raised. Positive read-through for IEX's water platform (FMT) and life sciences (HST); data center demand described as up 300%+ in orders. Implication: water infrastructure demand remains healthy; AI-driven water demand is accelerating.
• July 23, 2026 — Dover (DOV) Q2 2026 Results: DOV reported Q2 EPS of $2.74 (vs. $2.72 consensus) with organic revenue growth of +5% (slightly below +5.4% consensus). Full-year guidance raised: EPS to $10.55–$10.75 (from $10.45–$10.65) and organic growth to +4–6% (from +3–5%). Bookings grew double digits, book-to-bill at 1.06. Positive read-through for IEX's industrial order trends; heat exchanger demand for data center liquid cooling described as exceptional. Implication: broad industrial demand remains constructive heading into H2 2026.
• May 8, 2026 — Annual Shareholder Meeting (8-K): IDEX shareholders approved executive compensation and elected directors. Routine governance event; no operational or financial implications for Q2.
• April 29, 2026 — Q1 2026 Beat-and-Raise: Record orders of $988M (+10% organic), revenue of $887M (+5% organic), adj. EPS of $2.00 (+14% YoY), adj. EBITDA margin of 26.0% (+50 bps). Full-year organic growth guidance raised to +3–4% (from +1–2%); adj. EPS guidance raised $0.20 to $8.35–$8.55. HST organic orders +17%, driven by AI/data center, semiconductor, and space & defense. Implication: sets a high bar for Q2 order momentum but provides strong backlog visibility.
• Ongoing — Tariff Environment: IEEPA tariffs repealed and replaced with new tariffs at similar levels; management characterized net impact as largely neutral. IDEX applied for IEEPA refunds. Implication: no material headwind or tailwind expected in Q2 from tariff changes; pricing actions already embedded in guidance.
• Ongoing — AI/Data Center Demand Acceleration: Multiple peers (DOV, XYL) confirmed accelerating AI-driven demand for cooling, water treatment, and semiconductor-related components. IEX's HST segment (Airtech pneumatics, Mott filtration, optics) is directly exposed to this theme. Implication: secular tailwind remains intact and may be strengthening.

7. Peer Commentary Read-Throughs (Last 60 Days — Current Quarter / Forward-Looking Only)

Key Takeaway: Peer commentary from DOV (July 23) and XYL (July 28) is broadly constructive for IEX's Q2 setup — both confirm accelerating AI/data-center demand, healthy industrial order momentum, and improving water infrastructure trends. The only cautionary note is XYL's slight organic revenue guide trim due to electric metering project delays, which has no direct read-through to IEX.

Note: Only commentary explicitly addressing the current reporting quarter (Q2 2026), the remainder of 2026, or forward-looking end-market trends is included below. Retrospective Q1 2026 results commentary from peers has been excluded.

Dover Corporation (DOV) — Q2 2026 Earnings Call, July 23, 2026

Industrial Demand & Order Trends (Positive Read-Through for IEX FMT/FSDP)

• Bookings outpaced shipments and grew double digits in Q2, extending the streak of exceptional order rate momentum. Book-to-bill at 1.06 across all five segments simultaneously — a rare occurrence for DOV. “The strength and breadth of our order book provide improved visibility to our second half outlook.” → Positive read-through for IEX's FMT and FSDP order trends heading into Q2 print.
• Consolidated bookings up 15% on a trailing 12-month basis; book-to-bill well above one across the portfolio. “The breadth of our order growth is important and points to continued top line strength in the second half.” → Broad-based industrial demand remains constructive, supporting IEX's flattish FMT/FSDP guidance as a floor rather than a ceiling.
• Cycle durability: “I’m not aware of any kind of business right now where it looks like it’s short cycle demand that may end in 26. I don’t see anybody going negative moving into 27.” → Supports IEX management’s cautiously constructive tone on FMT/FSDP and reinforces the view that the industrial cycle has legs into 2027.
• Industrial M&A markets have improved: “Industrial M&A markets have improved this year, and our acquisition pipeline has a number of interesting opportunities in attractive end markets.” → Consistent with IEX management’s active bolt-on M&A pipeline commentary; supportive of IEX’s capital deployment strategy.

Data Center / Semiconductor (Positive Read-Through for IEX HST)

• Heat exchangers for liquid cooling of data centers delivered their best quarter ever; DOV is actively working to double capacity over the next 12 months. “Demand tied to data center infrastructure remains exceptional, with customers securing capacity well ahead of need.” → Directly corroborates IEX HST’s AI/data-center demand narrative; demand outpacing supply is a positive pricing signal.
• Semiconductor and electronics manufacturing: “Robust growth across our exposures to semiconductor and electronics manufacturing, where cryogenic components, flow meters and specialized heat exchangers position us well against a durable, multiyear investment cycle.” → Confirms the semiconductor capex cycle remains intact, a key driver of IEX HST’s organic growth.
• Secular growth markets now represent ~25% of DOV’s 2026 revenue (up from ~20% at end of Q1), with data center, semiconductor, biopharma, and space & defense leading. → Validates IEX’s strategic pivot toward these same end markets within HST.

Biopharma / Life Sciences (Mixed Read-Through for IEX HST Life Sciences)

• DOV's single-use biopharma connectors, pumps, and flow meters continue to benefit from investment in new therapies and the secular shift toward single-use batch manufacturing. “There is activity in the space and the systems are running and they’re consuming.” → Consumable-driven biopharma demand is healthy; positive read-through for IEX’s pharma sub-segment within HST life sciences.
• DOV noted its biopharma business is performing well due to new product introductions and the consumable nature of its revenue stream — contrasting with capital equipment peers (Danaher, Sartorius) that have faced more pressure. → Suggests IEX’s pharma exposure (described as “really, really strong” on the Q1 call) may continue to offset NIH/academic headwinds in Q2.

Margins & Pricing (Constructive Read-Through for IEX)

• DOV adj. EBITDA margin expanded 80 bps to 25.9% in Q2; incremental margins of 38% in Q2 vs. 25% in Q1. “Operational execution on incremental volume more than offset input cost inflation and facility consolidation costs.” → Positive read-through for IEX’s margin guidance of 26.5–27.0%; volume leverage is converting to margin expansion across the industrial sector.
• Full-year guidance raised: EPS to $10.55–$10.75 (from $10.45–$10.65); organic growth to +4–6% (from +3–5%). “As we look to the back half of the year, we are well positioned to drive continued value creation for our shareholders.”

Xylem Inc. (XYL) — Q2 2026 Earnings Call & Release, July 28, 2026

Water Infrastructure & Municipal Demand (Positive Read-Through for IEX FMT Water Platform)

• Municipal water demand remains healthy: “Demand in our municipal markets remains healthy, supported by strong infrastructure spending and backlog execution.” → Directly supports IEX’s Intelligent Water Solutions platform within FMT; municipal funding environment described as stable.
• Water orders up double digits in both Q1 and Q2 2026; XYL expects this to continue into H2. Water revenue expected to be up low single digits for the year with a strong second half. → Positive read-through for IEX’s FMT water platform, which management described as performing well with dual growth drivers (municipal + semiconductor high-purity water).
• Water infrastructure backlog built in H1; positive orders growth expected in H2. “The U.S. treatment market has been really positive for that business. And I think we expect that to continue in the second half.” → Supports IEX’s FMT water segment outlook; U.S. municipal infrastructure spending remains a durable tailwind.
• XYL’s digital water platform (View) growing ~30–40% in 2026, with discussions ongoing with industrial companies and verticals. → Validates IEX’s Intelligent Water Solutions technology overlay thesis; digital water intelligence is gaining traction with municipalities.

AI / Data Center & Semiconductor (Positive Read-Through for IEX HST)

• Data center revenue expected to increase ~200% in 2026; data center orders in Q2 up over 300%. “The growth of AI infrastructure is increasing the strategic importance of water across a broader industrial ecosystem from semiconductors and power generation to mining and other critical industries.” → Strongly corroborates IEX HST’s AI/data-center demand narrative; the AI ecosystem is driving demand across multiple industrial sub-sectors simultaneously.
• “We view data centres as an early indicator of a larger opportunity across the AI ecosystem, where water is increasingly becoming a critical input to infrastructure development and industrial growth.” → Supports IEX management’s framing of data center as a platform opportunity (not just a single-business exposure) across pneumatics, filtration, and optics within HST.
• XYL’s Water Solutions & Services (WSS) segment seeing a “big pickup in power” due to AI ecosystem energy needs, particularly nuclear expansion. → Incremental positive for IEX’s energy exposure, which management noted has “moved more to the green.”

Life Sciences (Positive Read-Through for IEX HST Life Sciences)

• XYL seeing “increasing demand across sectors such as food and beverage and life sciences, where water quality, reliability and operational performance are essential.” WSS segment focused on mining, life sciences, and food & beverage, expecting to “exit the year pretty strong.” → Positive read-through for IEX’s life sciences sub-segment within HST; demand for water-intensive life sciences applications is growing.

Industrial Order Trends & H2 Outlook (Constructive Read-Through for IEX FMT/FSDP)

• XYL anticipates “positive book-to-bill in the second half with high single-digit orders growth.” Ending backlog of $5.3B; book-to-bill well above one for Q2. → Broad industrial order momentum is intact heading into H2 2026.
• U.S. commercial buildings showing “resiliency”; XYL expects to “continue to build backlog here in the second half leading into a strong 27.” → Supports IEX’s view that general industrial business units are showing “signs of improvement.”
• Short-cycle exposure “fairly consistent” outside of data centers; Europe “bumping along a little bit.” → Consistent with IEX’s cautious FMT/FSDP guidance; European chemical and industrial softness remains a modest headwind.

Margins & Guidance (Constructive Read-Through for IEX)

• XYL raised full-year adj. EBITDA margin guidance to 23.1–23.5% (from 22.9–23.3%), representing 90–130 bps of expansion vs. prior year, driven by productivity, volume, and price. Q3 EBITDA margin guided to 23.5–24.0% (+30–80 bps). → Margin expansion is achievable across the industrial sector in H2 2026; positive read-through for IEX’s 26.5–27.0% Q2 margin guidance.
• XYL raised full-year adj. EPS guidance to $5.55–$5.70 (from $5.35–$5.60), driven by strong H1 performance, share repurchases, and higher margins. → EPS upside is achievable even with modest revenue headwinds; supports IEX’s EPS guidance raise trajectory.
• Tariff impact: “No material impact to our projected results from recently announced changes in tariffs or tariff refunds.” → Consistent with IEX’s characterization of tariff impact as largely neutral; no incremental headwind expected.

Cautionary Notes (Negative / Mixed Read-Throughs)

• XYL trimmed full-year organic revenue guidance to +2–3% (from +2–4%) due to electric metering project delays driven by “affordability concerns and a more cautious capital spending environment ahead of upcoming elections.” → Limited direct read-through for IEX — IEX has no electric metering exposure; the delay is utility-specific and not a broad industrial demand signal.
• China remains a “challenging market” for XYL; Q2 orders and sales down over 30%. → Incremental negative read-through for IEX’s life sciences sub-segment (China market pressure on end customers) and any China-exposed FMT businesses; consistent with IEX management’s existing cautious tone on China.
• M&A valuations “starting to soften a little bit” but “not aligned to where the market is.” → Consistent with IEX’s bolt-on focus at defined size/valuation discipline; no change to IEX’s M&A strategy implied.

Sources: Dover Corporation Q2 2026 Earnings Release and Earnings Call Transcript (July 23, 2026); Xylem Inc. Q2 2026 Earnings Release and Earnings Call Transcript (July 28, 2026).

8. Insider Transaction Activity

Key Takeaway: The only insider transaction since Q1 earnings was a discretionary open-market sale by CEO Eric Ashleman on May 11, 2026 — notable in size (~$3.4M) but not unusual given his tenure and existing position. No open-market buys were recorded. The absence of clustered buying or unusual selling patterns does not send a strong directional signal.

The CEO's discretionary sale of ~15,400 shares (~$3.4M) approximately 12 days after the Q1 beat-and-raise is worth noting but not alarming — Ashleman retained 66,658 shares post-transaction, representing a substantial ongoing economic interest. The sale was not executed under a 10b5-1 pre-planned trading program, which makes it a discretionary decision, but the timing (shortly after a strong print and stock surge) is a common pattern for executives monetizing gains. No other insiders filed Form 4 transactions in the period. Source: Insider Transaction Data (SEC Form 4 Filings).

9. Key Risks

Key Takeaway: The primary risk to the Q2 print is a deceleration in HST order momentum or margin compression from acquired-business mix — either would challenge the Street's already-conservative EPS consensus and could disappoint on the guidance trajectory for H2 2026.

• HST Order Deceleration (High Impact): Q1's record $988M orders and 17% HST organic order growth set a high bar. Any sequential deceleration in HST orders — particularly in data center or semiconductor — would raise questions about backlog durability and the H2/2027 growth outlook. Management guided Q2 HST at “high single-digit to double-digit” organic growth; a miss here is the single biggest downside risk.
• Life Sciences Headwinds Persist (Medium Impact): NIH/academic funding pressure and China market weakness in life sciences were flagged as ongoing headwinds in Q1. Management guided life sciences to return to flat-to-slight growth in H2 2026, but if the recovery is delayed, HST mix will be unfavorable and margin expansion will be harder to achieve. XYL's China commentary (orders/sales down 30%+) reinforces this risk.
• Acquired-Business Margin Drag (Medium Impact): Mott, Muon Micro, and Muon Lamb are all below HST's segment EBITDA average margin. The 8020 margin improvement process is multi-quarter; if incremental margins from these businesses disappoint, consolidated EBITDA margin could come in at the low end of the 26.5–27.0% guided range. This is likely the primary reason the Street's EPS consensus sits ~16% below the guidance midpoint.
• FMT/FSDP Industrial Recovery Timing (Medium Impact): Management guided FMT and FSDP as flattish for 2026, with a “touch of conservatism.” If chemical, general industrial, or dispensing end markets deteriorate further (rather than stabilizing as observed in March/April), FMT/FSDP could miss even the low bar. Global chemical softness (flagged by IEX and XYL) and European industrial weakness are the most likely triggers.
• Tariff / Trade Policy Uncertainty (Low-Medium Impact): While management characterized the net tariff impact as largely neutral, the evolving trade policy environment (flagged by DOV and XYL as an ongoing monitoring item) could create second-order effects on customer capital spending decisions, particularly in chemical and general industrial end markets.
• CEO Discretionary Stock Sale (Low Impact): Eric Ashleman's $3.4M open-market sale on May 11 was not under a 10b5-1 plan. While the retained position is substantial, the discretionary nature of the sale is a minor negative signal that bears monitoring if additional insider sales occur around the Q2 print.
• Valuation / Multiple Risk (Low-Medium Impact): IEX trades at 17.7x NTM EV/EBITDA and 25.0x NTM P/E. While not stretched relative to recent peaks, a miss on HST orders or margin guidance could trigger multiple compression given the premium embedded for secular growth. The 12-month price gain of +21% has been ~14% multiple expansion and only ~7% earnings growth — making the stock more vulnerable to a guidance cut than the absolute multiple suggests.